Patients with uncontrolled T2DM benefit from inhaled insulin
August 17th 2015Patients with poorly controlled type 2 diabetes (T2DM) experienced a significant decline in their HbA1c levels when adding Technosphere inhaled insulin (Afrezza, MannKind Corp.) to their current treatment regimen, according to a new study.